Assignee
ASKAT INC
JP·12 granted patents·3 pending applications·29 citations·filing 2014–2024
Top patents by PatentIndex Score
15 records- 0193US10947235B2Selective EP4 receptor antagonistic substance for treatment of cancerASKAT INC·Filed 2020·Granted Mar 16, 2021·3 cites·12 claims
- 0293US10611761B2Selective EP4 receptor antagonistic substance for treatment of cancerASKAT INC·Filed 2017·Granted Apr 7, 2020·7 cites·20 claims
- 0388US10583129B2Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancerASKAT INC·Filed 2019·Granted Mar 10, 2020·5 cites·8 claims
- 0486US10342785B2Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancerASKAT INC·Filed 2016·Granted Jul 9, 2019·4 cites·24 claims
- 0584US10391086B2Use of EP4 receptor antagonists in the treatment of cartilage diseaseASKAT INC·Filed 2018·Granted Aug 27, 2019·2 cites·8 claims
- 0683US12295962B2Polymorphic compounds and uses thereofASKAT INC·Filed 2024·Granted May 13, 2025·0 cites·12 claims
- 0783US9447066B2Salts and crystal formsASKAT INC·Filed 2014·Granted Sep 20, 2016·8 cites·11 claims
- 0874US11840530B2Selective EP4 receptor antagonistic substance for treatment of cancerASKAT INC·Filed 2021·Granted Dec 12, 2023·0 cites·21 claims
- 0966US2024352004A1Stable salt and crystal forms of 2-[3-({1-[2-(dimethylamino)ethyl]-2-(2,2-dimethylpropyl)-1h-1,3-benzodiazol-5-yl}sulfonyl)azetidin-1-yl]ethan-1-olASKAT INC·Filed 2024·Application pending·0 cites
- 1065US11964963B2Stable salt and crystal forms of 2-[3-({1-[2-(dimethylamino)ethyl]-2-(2,2-dimethylpropyl)-1H-1,3-benzodiazol-5-yl}sulfonyl)azetidin-1-yl]ethan-1-olASKAT INC·Filed 2021·Granted Apr 23, 2024·0 cites·26 claims
- 1160US10786490B2Use of EP4 receptor antagonists in the treatment of cartilage diseaseASKAT INC·Filed 2017·Granted Sep 29, 2020·0 cites·7 claims
- 1253US9561210B2Therapeutic agent for ocular diseaseASKAT INC·Filed 2014·Granted Feb 7, 2017·0 cites·4 claims
- 1351US2016317514A1Use of ep4 receptor antagonists in the treatment of cartilage diseaseASKAT INC·Filed 2014·Application pending·0 cites
- 1440US11555023B2Process for the differential solubility-driven asymmetric transformation of substituted 2H-chromene-3-carboxylic acidsASKAT INC·Filed 2020·Granted Jan 17, 2023·0 cites·8 claims
- 1539US2019365680A1Use of ep4 receptor antagonists for the treatment of nash-associated liver cancerASKAT INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ASKAT INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →